Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb20717 in Advanced Rare Cancers
NCT05337735Phase 2Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vudalimab in cancer, peritoneal mesothelioma, neuroendocrine carcinoma (NEC), cervical carcinoma, Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2022; status: suspended.
02
Drugs
vudalimab
03
Conditions
cancerperitoneal mesotheliomaneuroendocrine carcinoma (NEC)cervical carcinomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05337735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05337735.